BioAge Labs BIOA 深 滬
等待開盤 09-23 09:30:00 美东时间
8.46
+0.370
+4.57%
華盛通- 最 高8.53
- 今 開8.20
- 成交量 106.74万股
- 最 低 8.11
- 昨 收 8.09
- 總市值 3.88亿
- 52周最高 25.955
- 市盈率 靜 --
- 換手率 2.33%
- 52周最低 5.04
- 委 比 -82.02%
- 總股本 4589.69万
- 歷史最高 26.62
- 量 比 1.16
- 振 幅 5.19%
- 歷史最低 0.156
- 每 手 1
- 風險率 5.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.
09-08 23:25
BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomize...
09-08 20:06
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
BioAge Labs has initiated a Phase 2 trial (QUELL-DME) evaluating BGE-102, an oral NLRP3 inhibitor, for treating diabetic macular edema (DME). The randomized, controlled study involving ~180 participants will assess BGE-102 as monotherapy and in combination with anti-VEGF therapy, with the primary endpoint being change in best-corrected visual acuity at week 12. Topline results are expected in H2 2027. BGE-102's potential benefits extend to other ...
09-08 12:00
Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $2.451 million which...
08-06 05:19
美股牛股 | Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股
Atkore飙升逾28%，获电缆巨头大幅溢价收购！CoreWeave劲升近20%，新获木头姐增持29.8万股；AAOI升逾16%，英伟达官宣CPO步入量产提振板块>>
08-04 19:06
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies. William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial cast doubt...
08-01 01:24
